MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.11) by 9.09 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $6.829 million which missed the analyst consensus estimate of $8.370 million by 18.41 percent. This is a 16.35 percent decrease over sales of $8.164 million the same period last year.